Trials / Completed
CompletedNCT00242489
Etoricoxib in the Treatment of Osteoarthritis (MK-0663-007)
A Placebo-Controlled, Parallel-Group, Double-Blind Study to Assess Safety and to Define the Clinically Effective Dose Range of MK0663 in Patients With Osteoarthritis of the Knee, Followed by a Double-Blind, Active-Comparator-Controlled Extension.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1,167 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of etoricoxib in the treatment of osteoarthritis of the knee.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks) | |
| DRUG | Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks |
Timeline
- Start date
- 1998-06-01
- Primary completion
- 1999-02-01
- Completion
- 2002-07-01
- First posted
- 2005-10-20
- Last updated
- 2022-02-18
Source: ClinicalTrials.gov record NCT00242489. Inclusion in this directory is not an endorsement.